InsidersTradesSigma
Follow the Entero Therapeutics, Inc. share price and the full insider trade history of the company, a publicly traded company based in United States. Shares are quoted on US US, under the oversight of SEC (Form 4). Market capitalisation: €1.8bn. The latest transaction was reported on 8 January 2025 (Cession). Among the most active insiders: Romano Sarah. Every trade is free.
Analysts rate Entero Therapeutics, Inc. Strong Buy (bullish), based on 10 analysts. Average price target: US$57.10.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
5 of 5 declarations
Entero Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative treatments for gastrointestinal disorders. It is listed on the NASDAQ under the ticker symbol ENTR.